almagate has been researched along with Glaucoma, Suspect in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morshedi, RG; Ricca, AM; Wirostko, BM | 1 |
| Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
| Frenkel, MP; Frenkel, RE; Haji, SA | 1 |
| Choi, DY; Gorin, MB; Hubschman, JP; McCannel, CA; McCannel, TA; Ortube, MC; Sarraf, D | 1 |
| Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
| Bakri, SJ; Diehl, N; Hillemeier, J; Hodge, DO; McCannel, CA; Pulido, JS | 1 |
1 review(s) available for almagate and Glaucoma, Suspect
| Article | Year |
|---|---|
Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Bevacizumab; Humans; Intraocular Pressure; Intravitreal Injections; Nitric Oxide; Ocular Hypertension; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tonometry, Ocular; Vascular Endothelial Growth Factor A | 2016 |
5 other study(ies) available for almagate and Glaucoma, Suspect
| Article | Year |
|---|---|
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Ranibizumab; Retrospective Studies; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Aptamers, Nucleotide; Bevacizumab; Female; Filtering Surgery; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Ranibizumab; Retreatment; Retrospective Studies; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Injections, Intralesional; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Paracentesis; Remission, Spontaneous; Retinal Diseases; Triamcinolone | 2009 |